Back to top
more

Cambrex Corporation (CBM)

(Delayed Data from NYSE)

$46.20 USD

46.20
398,613

+2.73 (6.28%)

Updated May 3, 2019 04:02 PM ET

After-Market: $46.20 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bayer's sNDA for Stivarga Granted Priority Review in the U.S.

by Zacks Equity Research

Bayer (BAYRY) announced that the FDA has granted priority review designation to its sNDA for Stivarga for the second-line treatment of patients with uHCC.

    Bristol-Myers Extends Deal with Five Prime Therapeutics

    by Zacks Equity Research

    Bristol-Myers (BMY) has exercised its option to extend the research term of the existing collaboration agreement with Five Prime Therapeutics (FPRX).

      Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data

      by Zacks Equity Research

      Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.

        Clovis Declares Pricing of Upsized Offering of Common Stock

        by Zacks Equity Research

        Clovis Oncology, Inc. (CLVS) announced the pricing of its underwritten public offering of common stock worth $5 million.

          Allergan Natrelle Inspira Breast Implants Approved in the U.S.

          by Zacks Equity Research

          Allergan plc (AGN) announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.

            Inotek (ITEK) Down on Poor Phase III Glaucoma Drug Data

            by Zacks Equity Research

            Shares of Inotek Pharmaceuticals Corporation (ITEK) plunged 71.3% after the company announced that its lead candidate trabodenoson failed to meet the primary endpoint in a phase III trial.

              Kevin Matras headshot

              Get Ready To Be Surprised This Earnings Season

              by Kevin Matras

              Kevin Matras details a good screen to use before and after a company reports this earnings season. Highlighted stocks include MS, PMT, CBM, DTE and CHH.

                Sanofi (SNY) Closes Business Exchange Deal with Boehringer

                by Zacks Equity Research

                Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.

                  Incyte Treats First Patient in Phase II GVHD Study on Jakafi

                  by Zacks Equity Research

                  Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.

                    Corbus Concludes Phase II study of Cystic Fibrosis Candidate

                    by Zacks Equity Research

                    Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).

                      7 Stocks Near 52 Week-High with More Room to Run

                      by Zacks Equity Research

                      Meanwhile, the growing presence of high-valued stocks has made the market overvalued. In such a scenario, it may be naive to invest in value stocks.

                        ImmunoGen: Phase I Data on Ovarian Cancer Drug Published

                        by Zacks Equity Research

                        ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.

                          Achillion Receives $15M from J&J for HCV Study Enrolment

                          by Zacks Equity Research

                          Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.

                            Amphastar Stock Down on CRL for Asthma Drug in the U.S.

                            by Zacks Equity Research

                            Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).

                              Apricus Launches Vitaros in Lebanon for Erectile Dysfunction

                              by Zacks Equity Research

                              Apricus Biosciences, Inc. (APRI) announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd.

                                Neothetics (NEOT) Begins Phase II Study on Lead Candidate

                                by Zacks Equity Research

                                Neothetics, Inc. (NEOT) announced that it has commenced a phase II proof-of-concept study, LIPO-202-CL-31, on its lead candidate, LIPO-202, for the reduction of submental subcutaneous fat.

                                  Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold

                                  by Zacks Equity Research

                                  Seattle (SGEN) announced that the FDA had placed a clinical hold or partial clinical hold on several early-stage studies on SGN-CD33A for the treatment of AML.

                                    Horizon's Rare Disease Drug Quinsair Launched in Canada

                                    by Zacks Equity Research

                                    Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.

                                      Synergy Reports Positive Top-Line Phase III Data on IBS Drug

                                      by Zacks Equity Research

                                      Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the treatment of adult patients suffering from irritable bowel syndrome.

                                        Why MiMedx Group (MDXG) Could Be Positioned for a Slump

                                        by Zacks Equity Research

                                        While MiMedx Group (MDXG) may not be a good pick right now, you can consider other stocks in the same industry.

                                          Ionis Receives $5 Million Milestone from J&J Unit for GI Drug

                                          by Zacks Equity Research

                                          Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).

                                            Celgene's Otezla Gains Positive Recommendation from NICE

                                            by Zacks Equity Research

                                            Celgene Corporation (CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla.

                                              Cambrex (CBM): Moving Average Crossover Alert

                                              by Zacks Equity Research

                                              Are you a technical investor? If so, it may be time to consider Cambrex Corporation (CBM) for your portfolio.

                                                Teva Settles Foreign Bribery Charges with U.S. Government

                                                by Zacks Equity Research

                                                Teva (TEVA) announced that it has completed negotiations with the U.S. government over violations of the Foreign Corrupt Practices Act.

                                                  Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo

                                                  by Zacks Equity Research

                                                  Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).